Detection of a novel mutation at amino acid position 614 in the ryanodine receptor in malignant hyperthermia

British Journal of Anaesthesia

Volumn 79, Issue 3, 1997, Pages 332-337

  Quane, K A ^a   Ording, H ^b   Keating, K E ^a   Manning, B M ^a   Heine, R ^c   Bendixen, D ^b   Berg, K ^d   Krivosic Horber, R ^e   Lehmann Horn, F ^c   Fagerlund, T ^d   McCarthy, T V ^a  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF ULM   (Germany)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^e LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

Genetic factors, hyperthermia; Malignant hyperthermia; Receptors, ryanodine

Indexed keywords

AMINO ACID; ARGININE; INHALATION ANESTHETIC AGENT; LEUCINE; NEUROMUSCULAR BLOCKING AGENT; RYANODINE RECEPTOR;

AMINO ACID SUBSTITUTION; ARTICLE; AUTOSOMAL DOMINANT DISORDER; CLINICAL ARTICLE; DISEASE PREDISPOSITION; DNA DETERMINATION; FEMALE; GENE MUTATION; GENETIC SCREENING; HEREDITY; HUMAN; MALE; MALIGNANT HYPERTHERMIA; PHENOTYPE; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM; SKELETAL MUSCLE;

EID: 0030775059     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/79.3.332     Document Type: Article

References (32)

1. Ellis FR, Heffron JJA. Clinical and biochemical aspects of malignant hyperthermia. In: Atkinson RS, Adams AP, eds. Recent Advances in Anaesthesia and Analgesia. New York: Churchill-Livingstone, 1985; 173-207.
2. Gronert GA. Malignant hyperthermia. In: Engel AG, Banker BQ, eds. Myology. New York: McGraw-Hill, 1986; II: 1763-1784.
3. Britt BA, Kalow W. Malignant hyperthermia: a statistical review. Canadian Anaesthetists Society Journal 1970; 17: 293-315.
4. Mickelson JR, Gallant EM, Litterer LA, Johnson KM, Rempel WE, Louis CF. Abnormal sarcoplasmic reticulum ryanodine receptor in malignant hyperthermia. Journal of Biological Chemistry 1988; 263: 9310-9315.
5. Fujii J, Otsu K, Zorzato F, Leon S, Khanna K, Weiler JE, O'Brien PJ, MacLennan DH. Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science 1991; 253: 448-451.
6. Gillard EF, Otsu K, Fujii J, Khanna VK, De Leon S, Derdemez J, Britt BA, Duff CL, Worton RG, MacLennan DH. A substitution of cysteine for arginine 614 in the ryanodine receptor is potientially causative of human malignant hyperthermia. Genomics 1991; 11: 751-755.
7. Shy GM, Magee KR. A new congenital non-progressive myopathy. Brain 1956; 79: 610-621.
8. Quane KA, Healy JMS, Keating KE, Manning BM, Couch FJ, Palmucci LM, Doriguzzi C, Fagerlund TH, Berg K, Ording H, Bendixen D, Monier W, Linz U, Muller CR, McCarthy TV. Mutations in the ryanodine receptor gene in central core disease and malignant hyperthermia. Nature Genetics 1993; 5: 51-55.
9. Gillard E, Otsu K, Fujii J, Duff C, De Leon S, Khanna VK, Britt BA, Worton RG, MacLennan DH. Polymorphisms and deduced amino acid substitutions in the coding sequence of the ryanodine receptor (RYRl) gene in individuals with malignant hyperthermia. Genomics 1992; 13: 1247-1254.
10. Quane KA, Keating KE, Manning BM, Healy JMS, Monsieurs K, Heffron JJA, Lehane M, Heytens L, Krivosic-Horber R, Adnet P, Ellis FR, Monnier N, Lunardi J, McCarthy TV. Detection of a novel common mutation in the ryanodine receptor gene in malignant hyperthermia: Implications for diagnosis and heterogeneity studies. Human Molecular Genetics 1994; 3: 471-476.
11. Quane KA, Keating KE, Healy JMS, Manning BM, Krivosic-Horber R, Krivosic I, Monnier N, Lunardi J, McCarthy TV. Mutation screening of the RYR1 gene in malignant hyperthermia: detection of a novel Tyr to Ser mutation in a pedigree with associated central cores. Genomics 1994; 23: 236-239.
12. Keating KE, Quane KA, Manning BM, Lehane M, Hartung E, Censier K, Urwyler A, Klausnitzer M, Muller CR, Heffron JJA, McCarthy TV. Detection of a novel RYR1 mutation in four malignant hyperthermia pedigrees. Human Molecular Genetics 1994; 3: 1855-1858.
13. Philips MS, Khanna VK, De Leon S, Frodis W, Britt BA, MacLennan DH. The substitution of Arg for Gly2433 in the human skeletal muscle ryanodine receptor is associated with malignant hyperthermia. Human Molecular Genetics 1994; 3: 2181-2186.
14. Zhang Y, Chen HS, Khanna VK, De Leon S, Philips M, Schappert K, Britt BA, Brownell AKW, MacLennan DH. A mutation in the human ryanodine receptor gene associated with central core disease. Nature Genetics 1993; 5: 46-49.
15. Phillips MS, Fuji J, Khanna VK, DeLeon S, Yokobata K, Dejong PJ, MacLennon DH. The structural organisation of the human skeletal muscle ryanodine receptor (RYRl) gene. Genomics 1996; 34: 24-41.
16. Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Analytical Biochemistry 1987; 162: 156-159.
17. Rychlik W, Rhoads RE. A computer program for choosing optimal oligonucleotides for filter hybridisation, sequencing and in vitro amplification of DNA. Nucleic Acids Research 1989; 17: 8543-8551.
18. 2+ release channel (ryanodine receptor) of skeletal muscle sarcoplasmic reticulum. Journal of Biological Chemistry 1990; 265: 2244-2256.
19. Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 1989; 5: 874-879.
20. Old JM, Higgs DR. In: Weatherall D, ed. Methods in Haematology. Edinburgh: Churchill-Livingstone, 1983; 74.
21. European Malignant Hyperpyrexia Group. A protocol for investigation of malignant hyperpyrexia susceptibility. British Journal of Anaesthesia 1984; 56: 1267-1271.
22. Deufel T, Sudbrak R, Feist Y, Rubsam B, Du Chesne I, Schafer K-L, Roewer N, Grimm T, Lehmann-Hom F, Hatung EJ, Muller CR. Discordance, in a malignant hyperthermia pedigree, between in vitro contracture-test phenotypes and haplotypes for the MHS1 region on chromosome 19ql2-13.2, comprising the C 184OT transition in the RYR1 gene. American Journal of Human Genetics 1992; 50: 1153-1161.
23. Larach MG, Localio AR, Allen GC, Denborough MA, Ellis FR, Gronert GA, Kaplan RF, Muldoon SM, Nelson TE, Ording H, Rosenberg H, Waud BE, Wedel DJ. A clinical grading scale to predict malignant hyperthermia susceptibility Anesthesiology 1994; 80: 771-779.
24. 2+ release channel (ryanodine receptor) of rabbit cardiac muscle sacroplasmic reticulum. Journal of Biological Chemistry 1990; 265: 13472-13483.
25. Hakamata Y, Nakai J, Takeshima H, Imoto K. Primary structure and distribution of a novel ryanodine receptor/ calcium release channel from rabbit brain. FEBS Letters 1992; 312: 229-235.
26. Oyamada H, Murayama T, Takagi T, Lino M, Iwabe N, Miyata T, Ogawa Y, Endo M. Primary structure and distribution of the ryanodine-binding protein isoforms of bullfrog skeletal muscle Journal of Biological Chemistry 1994; 269: 17206-17214.
27. Takeshima H, Nishi M, Iwabe N, Miyata T, Hosoya T, Masai I, Hotta Y. Isolation and characterisation of a gene for a ryanodine receptor/calcium release channel in Drosophila melanogaster. FEBS Letters 1994; 337: 81-87.
28. Sheen J-C, Rideout WM III, Jones PA. Cell 1992; 71: 1073-1080.
29. Cooper DN, Youssufian H. The CpG dinucleotide and human genetic disease. Human Genetics 1988; 78: 151-155.
30. MacLennan DH, Phillips MS. Malignant hyperthermia. Science 1992; 256: 789-794.
31. Lynch PJ, Krivosic-Horber R, Reyford H, Monnier N, Quane K, Adnct P, Haudercoeur G, Krivosic I, McCarthy TV, Lunardi J. Identification of heterozygous and homozygous individuals with the novel RYR1 mutation Cys35Arg in a large kindred. Anesthesiology 1997; 86: 620-626.
32. Keating KE, Giblin L, Lynch PJ, Quane KA, Lehane M, Heffron JJA, McCarthy TV. Detection of a novel mutation in the ryanodine receptor gene in an Irish malignant hyperthermia pedigree: correlation of the IVCT response with the affected and unaffected haplotypes. Journal of Medical Genetics 1997; 34: 291-296.